146 patents
Page 2 of 8
Utility
Methods of Using EHMT2 Inhibitors
23 Mar 23
The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof.
John Emmerson CAMPBELL, Kenneth William DUNCAN, Elayne PENEBRE, Kat COSMOPOULOS, Christine KLAUS
Filed: 14 Sep 21
Utility
Use of EZH2 inhibitors for treating cancer
14 Mar 23
The disclosure provides methods of treating, identifying and/or selecting for treatment a subject having a cancer in which an immune checkpoint protein is upregulated.
Scott Daigle, Kat Cosmopoulos
Filed: 1 Jun 18
Utility
Substituted Indoles and Methods of Use Thereof
9 Mar 23
John LAMPE, John CAMPBELL, Kenneth DUNCAN, Megan Alene Cloonan FOLEY, Darren Martin HARVEY, Michael John MUNCHHOF, Michael THOMENIUS, Lawrence Alan REITER
Filed: 14 Aug 19
Utility
Crebbp Related Cancer Therapy
16 Feb 23
The present disclosure provides novel cancer therapies.
Alexandra Grassian, Scott Ribich, Jesse Smith, Darren Martin Harvey
Filed: 9 Feb 22
Utility
Methods of Treating WHSC1-OVEREXPRESSING Cancers by Inhibiting SETD2
16 Feb 23
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
Michael THOMENIUS, Katherine Louise COSMOPOULOS, Jennifer Anne TOTMAN
Filed: 26 Nov 19
Utility
Methods of synthesizing substituted purine compounds
7 Feb 23
The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Edward J. Olhava
Filed: 18 Sep 20
Utility
Inhibition of SMARCA2 for Treatment of Cancer
5 Jan 23
The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer.
Alexandra Rose GRASSIAN, Allison DREW
Filed: 24 Jun 22
Utility
Combination Therapy for Treating Cancer
5 Jan 23
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount.
Maria Alejandra RAIMONDI, Dorothy BRACH
Filed: 22 Aug 22
Utility
Arginine methyltransferase inhibitors and uses thereof
29 Nov 22
Richard Chesworth, Lorna Helen Mitchell, Gideon Shapiro, Kerren Kalai Swinger
Filed: 27 Aug 20
Utility
PYRIDIN-2-ONE Compounds Useful As SMARCA2 Antagonists
10 Nov 22
Oscar Moradei, John W. Lampe, Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan, Michael John Munchhof
Filed: 24 Jul 19
Utility
Salt form of a human histone methyltransferase EZH2 inhibitor
8 Nov 22
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide.
Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
Filed: 25 Sep 20
Utility
Amine-substituted Heterocyclic Compounds As EHMT2 Inhibitors, Salts Thereof, and Methods of Synthesis Thereof
13 Oct 22
The present disclosure relates to amine-substituted heterocyclic compounds.
John Emmerson CAMPBELL, Kenneth William DUNCAN, James Edward John MILLS, Michael John MUNCHHOF
Filed: 24 Mar 22
Utility
Methods of Treating Cancer
6 Oct 22
The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
Sarah K. KNUTSON, Natalie WARHOLIC, Heike KEILHACK
Filed: 8 Mar 22
Utility
Combination therapy for treating cancer
27 Sep 22
The disclosure relates to methods, compounds for use and medicaments for the treatment of cancer comprising administering to a subject in need thereof a first agent in a therapeutically effective amount and one or more second agents each in a therapeutically effective amount.
Maria Alejandra Raimondi, Dorothy Brach
Filed: 5 Sep 18
Utility
Use of EZH2 Inhibitors for Treating Cancer
15 Sep 22
The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor.
Scott RIBICH, Michael THOMENIUS
Filed: 1 Jun 17
Utility
Combination Therapy for Treating Cancer
8 Sep 22
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike KEILHACK, Sarah Kathleen KNUTSON, Kevin Wayne KUNTZ
Filed: 23 May 22
Utility
Substituted Fused Bi- or Tri- Heterocyclic Compounds As EHMT2 Inhibitors
1 Sep 22
The present disclosure relates to substituted fused bi- or tri-heterocyclic compounds.
John Emmerson CAMPBELL, Kenneth William DUNCAN
Filed: 23 Dec 21
Utility
Compounds Containing a Sulfonic Group As Kat Inhibitors
25 Aug 22
Darren Martin Harvey
Filed: 29 Nov 17
Utility
Amine-substituted Heterocyclic Compounds As EHMT2 Inhibitors and Methods of Use Thereof
28 Jul 22
The present disclosure relates to amine-substituted heterocyclic compounds.
John Emmerson CAMPBELL, Kenneth William DUNCAN
Filed: 15 Nov 21
Utility
Combination Therapy for Treating Cancer
21 Jul 22
The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Heike KEILHACK, Sarah K. KNUTSON, Kevin W. KUNTZ
Filed: 23 Nov 21